The Role of Protein FOXA1 in Tamoxifen Resistance in ILC

Lobular Breast Cancer Alliance (LBCA) Scientific Advisory Board (SAB) Chair and Dana Farber Oncologist Dr. Rinath Jeselsohn recently talked to LBCA’s Executive Director Laurie Hutcheson about her latest invasive lobular carcinoma (ILC) study A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. The research was published in AACR’s Cancer Research in August. Past SAB Chair Dr. Otto Metzger was a co-author.

The goal of this  study was to better understand the unique features of the estrogen receptor in lobular breast cancer. In particular, the researchers sought to investigate what role the protein FOXA1 may play in limiting the effectiveness of Tamoxifen in repressing ILC tumor growth. Watch the interview below.

For more information about lobular breast cancer or to make a gift visit

Share this article:
Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.